anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background and Objectives: The aim of this study was to assess any predisposing factors to the morbidity of fashioning and reversal of diverting ileostomy in a prospective cohort of patients who have undergone TME and low colo-rectal or colo-anal anastomosis for rectal cancer. Materials and Methods: Consecutive patients with rectal cancer undergoing low anterior resection and a defunctioning loop ileostomy in three surgical units from 2016 to 2020 were included in the study and retrospectively analyzed. Results: One hundred eighty-two patients from three centres were included. Ileostomy-related mortality was 0.5%, attributed to renal failure.. Ileostomy-related morbidity was 46%. Postoperative ileus was seen in 37.4%, and dehydration in 18.8% of the patients. The readmission rate for ileostomy-related reasons was 15.4%. Stoma care was problematic in 15.7% or poor in 7% of the cases. Advanced age, male gender and obesity were independent risk factors for ileostomy-related morbidity. Ileostomy was reversed in 165 patients. The morbidity in 165 patients was 16%. Ileus was seen in 10.3%, anastomotic leak in 4.8% and wound infection in 12.7% of the cases. One patient died because of an anastomotic leak. No predisposing factors that affect the outcomes of ileostomy closure were identified. Conclusions: Diverting ileostomy-related morbidity is high. Life threatening dehydration and renal failure from ileus is more commonly seen in elderly, male and obese patients and should be anticipated. Ileostomy closure-related morbidity is low.
Patients will be recruited from the Severe Asthma Clinics at Royal Brompton Hospital. At the first visit the investigators will enrol and characterise patients. This will involve asking patients to keep a diary record of PEFR(Peak Expiratory Flow Rate), spirometry, symptom scores, use of beta-agonist reliever and other treatments for 2 weeks. Bloods tests will be taken for markers of systemic inflammation. Markers of oxidative stress will be measured in blood, exhaled breath condensate (EBC) and urine: malondialdehyde (MDA) and 8-isoprostanes. Nitric oxide (NO) levels in exhaled breath will be measured measured twice daily for 2 weeks using a portable hand-held NO meter. If spontaneous sputum is not available, sputum will be induced using ultrasonic nebulization of isotonic saline. Profile of inflammatory cells, cytokines in supernatants, bacteriological culture and microbiome analysis will be measured in the sputum. Patients will be observed over 12 months during which time the number of exacerbations will be recorded on basis of objective measures with evaluation of ACQ (Asthma Control Questionnaire), daily morning and evening PEF (Peak Expiratory Flow). At the earliest onset of exacerbation, the patient will be requested to contact the Asthma Research Unit. Patients will then be asked to attend the laboratory where similar tests to the first visit will be performed. For other exacerbations not studied, the patient will be asked to keep a detailed diary record of symptoms with severity scoring and spirometric and PEF measurements (Exacerbation Diary) over a period of 2 weeks after onset of exacerbation.

As patients with severe asthma are usually very well experienced in what the symptoms of exacerbations are, they will therefore be asked to recognise their own exacerbations. Each patient has their own way of recognising an exacerbation and the investigators will discuss this with each patient and try and establish whether an earlier warning signal is possible. Patients will be asked to record their symptoms and lung function as soon as they feel the onset of an exacerbation, since exacerbations are recognised by the patient as events that are 'clinically identified by being outside the patient's usual range of day-to-day variation'. The patient will receive or administer treatments for the exacerbation as usual without interference from the Research Team except for starting any antibiotic therapies, which will be started (if prescribed) as soon as the visit studies have been completed. Those who have been hospitalized will not be studied, and only those who can attend the Clinical Research Unit will be studied.
FIELD: molecular biology, genetic engineering. SUBSTANCE: fragment of genome DNA from human ischiatic nerve encoding ciliary neurotrophic factor (SN-CNTF) is cloned and sequenced. DNA sequence that can be used for human SN-CNTF expression in E. coli cells is obtained and recombinant expression vectors involving the indicated sequence are constructed. After transformation of suitable E. coli strain with the indicated vectors, selection and culturing transformants an active form of human recombinant SN-CNTF is isolated from bacterial cells. Its molecular mass is 24 kDA and its N-terminal amino acid sequence is identical with that of native protein sequence. EFFECT: improved method of protein factor preparing. 5 cl, 1 tbl, 22 dwg
In a new process for stabilising an aq pharmaceutical injection soln contg. 30-80 mol noramidopyrine-methanesulphonate (II) psi 100 mol phenylbutazone (I), both dissolved as alkali salts, 30-60 mol ethylene diamine are added psi 100 mol phenylbutazone. Ethylenediamine is pref used in an amount of 40-50 mol psi 100 mol (I). In a pref procedure. (I) is first dissolved in water followed by (II) (NaOH being added if necessary to convert them into their Na salts), then ethylenediamine is added with agitation and the resulting soln is agitated at least a further hour. Addn ethylenediamine and subsequent agitation are esp carried out under nitrogen gassing. Addn of ethylenediamine stabilises the soln. preventing the formation of a ppte due to chemical reaction between (I) and (II). The injection solns are useful as antirheumatic agents.
The goal of this two-year study is to test the efficacy of dronabinol as an adjunct to maintenance treatment with naltrexone in opioid-dependent individuals. We are proposing a randomized, double-blind, placebo controlled, parallel-groups, 8 week study of relapse prevention in opioid-dependent individuals. Participants will be randomized into one of two conditions (1) Naltrexone and Placebo (N=20) and (2) Naltrexone and dronabinol 15 mg bid (N=40). Treatment will be delivered in an outpatient setting except for the initial phase of inpatient detoxification, lasting 8 days. A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections), while dronabinol or placebo will be taken daily. In addition, patients will receive a psychosocial intervention that will include elements of motivational interviewing and cognitive-behavioral relapse prevention therapy. The primary aim is to test the efficacy of dronabinol in improving tolerability of naltrexone induction and reducing attrition during detoxification and the first two months of naltrexone treatment. The primary outcome will be the severity of opiate withdrawal and craving. The secondary outcome will be will be retention in treatment at study's end.
The invention relates to variants of interleukin-2 (IL2). In particular, the invention relates to a polypeptide comprising a mutein of human IL2 or of a functional variant of human IL2, wherein the human IL2 or functional variant thereof is substituted such that affinity for the ß? IL2 receptor complex (?L2Rß?) is enhanced. In one embodiment, the human IL2 or functional variant thereof is further substituted such that affinity for the aß? IL2 receptor complex (IL2aß?) is reduced. In one embodiment, the polypeptide activates effector T cells over regulatory T cells. The invention also relates to polynucleotides coding for the polypeptides of the invention, host cells comprising the polynucleotides, pharmaceutical compositions comprising the polypeptides, polynucleotides or host cells, therapeutic or prophylactic methods of treatment using the polypeptides, polynucleotides, host cells or pharmaceutical compositions and medical preparations comprising the polypeptides, polynucleotides, host cells or pharmaceutical compositions.
A purified RNA proteo-lipid complex is obtained from the body fluids of patients whose serum contains no lipoprotein a or from an extract or culture residue thereof. The suspension is decontaminated by column chromatography over agarose. This is preferably followed by purification in an affinity column prepared by coupling anti human serum globulins with agarose activated by cyanogen bromide. A monoclonal antibody for the RNA proteo-lipid complex is produced from hybridoma cells which do not produce antibodies which react with normal serum. The hybridoma cells can be multiplied in vivo. The RNA proteo-lipid complex or the monoclonal antibody can be connected covalently to a ligand. Single-strand desoxyribonucleic acid complementary to the RNA proteo-lipid complex is obtained by forming a cDNA by inverse transcription, by introducing the cDNA provided with linkers into a bacteriophage, transforming Escherichia coli, cloning and isolating the cDNA, and then converting it to a single-strand cDNA. These substances can be used to detect the RNA proteo-lipid complex formed by malignant human cells present in the serum or the cells of a patient or the antibodies of the RNA proteo-lipid complex.
The invention discloses a sponge-derived biocontrol Streptomyces (Streptomyces sp.) ITBB-ZK-a5 and a biocontrol product for preventing and treating crop and aquaculture animal diseases, which comprises the biocontrol Streptomyces (Streptomyces sp.) ITBB-ZK-a5, wherein the sponge-derived biocontrol Streptomyces (Streptomyces sp.) ITBB-ZK-a5 and the biocontrol product have control effects on various pathogenic bacteria. Also discloses application of the sponge-derived biocontrol Streptomyces (Streptomyces sp.) ITBB-ZK-a5 and a biocontrol product comprising the biocontrol Streptomyces (Streptomyces sp.) ITBB-ZK-a5 in preparation of a medicament with pathogenic fungus and pathogenic bacteria preventing and treating effects.
Cognitive reappraisal is a psychotherapeutic strategy utilized to regulate emotions by reinterpreting the meaning of stimuli. Participants will receive instructions on generating and implementing cognitive reappraisal in both misophonic and non-misophonic contexts and will be practicing it within psychotherapeutic sessions. The program consists of four weekly online psychotherapeutic sessions: the first session will be a 90-minute group session, followed by three individual sessions, each lasting 30 minutes.
Patients in the experimental group will be informed about the using virtual reality glasses during the taking blood. During this process, their anxiety and pain will be assesed. Patients in the study group will be evaluated 2 times, before the intervention and after the intervention, through data collection tools.
BACKGROUND: Chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) leads to severe discomfort in males and loss of sperm quality. Current therapeutic options have failed to achieve satisfactory results. Sodium butyrate (NaB) plays a beneficial role in reducing inflammation, increasing antioxidant capacities, and improving organ dysfunction; additionally NaB has good safety prospects and great potential for clinical application. The purpose of the current research was to study the effect of NaB on CP/CPPS and the underlying mechanisms using a mouse model of experimental autoimmune prostatitis (EAP) mice.
METHODS: The EAP mouse model was successfully established by subcutaneously injecting a mixture of prostate antigen and complete Freund's adjuvant. Then, EAP mice received daily intraperitoneal injections of NaB (100, 200, or 400 mg/kg/day) for 16 days, from Days 26 to 42. We then explored anti-inflammatory potential mechanisms of NaB by studying the effects of Nrf2 inhibitor ML385 and HO-1 inhibitor zinc protoporphyrin on prostate inflammation and pelvic pain using this model. On Day 42, hematoxylin-eosin staining and dihydroethidium staining were used to evaluate the histological changes and oxidative stress levels of prostate tissues. Chronic pelvic pain was assessed by applying Von Frey filaments to the lower abdomen. The levels of inflammation-related cytokines, such as interleukin (IL)-1β, IL-6, and tumor necrosis factor were detected by enzyme-linked immunosorbent assay. The regulation of Nrf2/HO-1 signaling pathway and the expression of NLRP3 inflammasome-related protein in EAP mice were detected by western blot analysis assay.
RESULTS: Compared with the EAP group, chronic pain development, histological manifestations, and cytokine levels showed that NaB reduced the severity of EAP. NaB treatment could inhibit NLRP3 inflammasome activation. Mechanism studies showed that NaB intervention could alleviate oxidative stress in EAP mice through Nrf2/HO-1 signal pathway. Nrf2/HO-1 pathway inhibitors can inhibit NaB -mediated oxidative stress. The inhibitory effect of NaB on the activation of NLRP3 inflammasome and anti-inflammatory effect can also be blocked by Nrf2/HO-1 pathway.
CONCLUSIONS: NaB treatment can alleviates prostatic inflammation and pelvic pain associated with EAP by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO-1 pathway. NaB has the potential as an effective agent in the treatment of EAP.
The invention discloses a traditional Chinese medicine composition for treating external hemorrhoids and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition consists of the following raw materials by mass: 2-4g of squama manis powder, 4-6g of dried alum and 1-3g of chalcanthite. The preparation method comprises the steps of grinding squama manis in a grinding machine and putting the ground squama manis into a mortar for grinding; passing a 200-mesh sieve; preparing the squama manis powder; and mixing the squama manis powder with the dried alum and the chalcanthite, putting a mixture into the mortar for grinding for 1-2 hours, and putting the ground mixture into a drying box with the temperature of 40-50 DEG C for drying to obtain the traditional Chinese medicine composition. The traditional Chinese medicine composition has a very good treatment effect. A clinical case shows that the traditional Chinese medicine composition has the cure rate of more than 85% and the total efficiency of 98%. The raw materials are easily available and the cost is low. The treatment process is safe, noninvasive, free of toxic and side effects, and free of various pains of operation. The traditional Chinese medicine composition is convenient and flexible to use, and does not have any influence on life and work of patients.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to gynecology and physiotherapy, and can be used to treat chronic salpingo-oophoritis. To do this, rehabilitation of infection foci is carried out and enzyme preparation is used. As enzyme preparation, drug Fermencol is used, dissolved in preparation Solactin at a concentration of 0.1–0.2 mg/ml. "Fermencol" is administered by intravaginal electrophoresis at initial current strength of 0.1 mA, followed by increase in it during the session to 2 mA, focusing on patient's feelings, with maximum current density of not more than 0.1 mA/cm. At the same time as active electrode using vaginal electrode produced by LLC INISS-med. As a passive electrode, electrode with conductive tissue moistened with saline, located on lumbosacral area is used. Treatment session is carried out for 15 minutes, daily, in course of 15 days.EFFECT: method provides increase in effectiveness and accessibility of treatment, reduction in duration of treatment, achievement of stable remission, and improvement in reproductive function with no side effects.1 cl, 2 ex
Beginning 21 days after randomization, patients undergo SBRT for 3-8 treatments every 2 days or QD over 1-3 weeks. Patients undergo FDG-PET/CT during screening. Patients undergo blood sample collection and CT scans throughout the trial.
Of the individuals identified in the screener survey endorsing past year mental health symptoms, half will be randomized into the control group. The control group will not be contacted. The investigators will passively monitor their posts on RallyPoint for the duration of the study (6 months).
The study will recruit 235 dyads of adult ARF survivors and care partners. The term "care partner" refers to an individual (e.g. family member or friend) that supports the survivor at home.
Surgical aortic valve replacement (AVR) is recommended for severe aortic valve disease. Bioprosthesis remains the substitute of choice for elderly patients. However, it may be associated with patient-prosthesis mismatch particularly for patients with small aortic annulus. Moreover, "valve-in-valve" transcatheter aortic valve replacement (TAVR) has become a suitable therapeutic option for bioprosthesis structural degeneration, especially in patients with high surgical risk. It is therefore of great importance to implant the widest bioprosthesis as possible at the first AVR. The investigators report a surgical technique allowing the implantation of a larger bioprosthesis in patients with small aortic annulus: the supra-annular aortic valve replacement (SA-AVR) above the aortic annulus. The investigators analyzed the postoperative outcomes of the SA-AVR technique using the Perimount Magna Ease (Carpentier-Edwards, Irvine, California) bioprosthesis.
Small fiber polyneuropathy (SFPN) is diagnosed through a combination of symptoms, signs and confirmatory diagnostic testing. Nerve conduction studies are not sensitive enough in most of the cases leaving the ankle skin biopsy with measurement of intraepidermal nerve fiber density (IENFD) as the main diagnostic tool. Despite its utility and reproducibility, skin biopsy is invasive, expensive and requires a central laboratory for processing and interpretation. Quantitative sudomotor axon reflex testing (QSART) is also routinely used for evaluation of small fiber neuropathy as sudomotor axons can also be involved. This test however remains technically challenging and requires testing conditions in specialized labs that are not always suitable for all patients' population. By comparing findings on skin biopsy and/or QSRT, accepted gold standard for diagnosing SFPN, the investigators seek to find faster, less-invasive ways to diagnose and monitor small-fiber polyneuropathy in rare diseases using Sudoscan measurement.
BACKGROUND: Acute upper respiratory infection (AURI) is a significant disease affecting all age groups worldwide. The differences in the impacts of different temperature change indicators, such as diurnal temperature range (DTR), temperature variation (TV), and temperature change between neighboring days (TCN), on AURI morbidity, are not clear.
METHODS: We collected data on 87,186 AURI patients during 2014-2019 in Zhengzhou. Distributed lag non-linear model was adopted to examine the effects of different temperature change indicators on AURI. We calculated and compared the attributable fractions (AF) of AURI morbidity caused by various indicators. We used stratified analysis to investigate the modification effects of season and gender.
RESULTS: With the increase in DTR and TV, the risk of AURI tended to increase; the corresponding AF values (95% eCI) higher than the references (5% position of the DTR or TV distribution) were 24.26% (15.46%, 32.05%), 23.10% (15.59%, 29.20%), and 19.24% (13.90%, 24.63%) for DTR, TV0 - 1, and TV0 - 7, respectively. The harmful effects of TCN on AURI mainly occurred when the temperature dropped (TCN < 0), and the AF value of TCN below the reference (0°C) was 3.42% (1.60%, 5.14%). The harm of DTR and TV were statistically significant in spring, autumn and winter, but not in summer, while the harm of TCN mainly occurred in winter. Three indicators have statistically significant effects on both males and females.
CONCLUSIONS: High DTR and TV may induce AURI morbidity, while the harm of TCN occurs when the temperature drops. The impacts of DTR and TV on AURI are higher than that of TCN, and the impact of few-day TV is higher than that of multi-day TV. The adverse effects of DTR and TV are significant except in summer, while the hazards of TCN mainly occur in winter.
This prospective randomized controlled trial included 80 eyes of 40 patients having routine phacoemulsification of cataract. Patients between 40 and 80 years of age who met enrollment criteria, required cataract surgery in both eyes, and agreed to participate, were enrolled in the study over a nine month period in 2006 at the office of one cataract surgeon. Eyes were randomly assigned to receive either the eye drop or injection protocol on the initial consultative visit. All surgery was preformed by one surgeon (JGS) using topical anesthesia, the Infiniti phacoemulsification system (Alcon) and an Acrysof SN60WF (Alcon) intraocular lens. The fellow eye was operated upon using the same technique and instrumentation two weeks later and was assigned to the group opposite the first eye. All eyes were examined by the operating surgeon at days 1, 8, 15, 30 and 90 postoperatively with uncorrected visual acuity, best corrected visual acuity, intraocular pressure, corneal edema, anterior chamber cell and flare recorded.
PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots. If benefits are obtained, 12 weeks of treatment is followed by spaced maintenance sessions at timing of provider and patient discretion.
Each session of mantra meditation lasts for 30 minutes. The participants in each session comprise 1 subject and the PI. In each session, the subject and the PI co-participate in repetitive intonation of a pre-specified mantra. Intervention is comprised of 9 sessions, each of which occurs on a separate weekday at approximately equal intervals over a total intervention period of 3 weeks.